Instil Bio, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Instil Bio, Inc. (TIL) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$55.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-13
- Instil Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$55.00K.
- Instil Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was $51.00K.
- Instil Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $193.00K, a 80.37% increase year-over-year.
- Instil Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was -$354.00K.
- Instil Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was -$355.00K, a 395.83% decline from fiscal 2024.
- Instil Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $120.00K, a 17.24% decline from fiscal 2023.
- Instil Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $145.00K.
- Instil Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$406.00K, a 307.14% decline from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$55.00K 10-Q · filed 2026-08-13 | -$4.00K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $51.00K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | -$355.00K 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $193.00K 10-Q · filed 2025-11-13 | -$161.00K derived: sum of 2 quarters · filed 2026-08-13 | -$384.00K derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | -$354.00K 10-Q · filed 2026-08-13 | -$577.00K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | -$223.00K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $120.00K 10-K · filed 2026-03-27 | |||
| 2024-09-30 | $107.00K 10-Q · filed 2025-11-13 | $43.00K derived: sum of 2 quarters · filed 2025-11-13 | -$172.00K derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$64.00K 10-Q · filed 2025-11-13 | -$279.00K derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | -$215.00K 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $145.00K 10-K · filed 2025-03-04 | |||
| 2023-09-30 | $270.00K 10-Q · filed 2024-11-13 | -$119.00K derived: sum of 2 quarters · filed 2024-11-13 | -$32.00K derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$389.00K 10-Q · filed 2024-11-13 | -$302.00K derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $87.00K 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | -$406.00K 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $222.00K 10-Q · filed 2023-11-13 | $106.00K derived: sum of 2 quarters · filed 2023-11-13 | -$248.00K derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$116.00K 10-Q · filed 2023-11-13 | -$470.00K derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | -$354.00K 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $196.00K 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $106.00K 10-Q · filed 2022-11-14 | |||
| 2021-03-31 | $30.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |